Hi Barney & MAC, this is really excellent news. In fact the timing is absolutely perfect, Pacific Edge Diagnostics are into a commercial roll-out with ‘User Program’ data becoming available; best test on the market and statistically better (published results) than the incumbents (cytology, BTA, NMP22 etc.).
A totally independent and thorough investigation and, for
CxBladder to be included really means it is well and truly on the radar in the United States.
To be published in such a wide ranging review that will encompass all clinical practices and challenge (review) all process will certainly put
CxBladder directly under the noses of urologists, GP’s and clinicians.
The American
AHRQ (Agency for Healthcare Research and Quality) has commissioned the Effective Health Care Program to complete a review of the evidence for:
PROJECT NAME: Emerging Approaches to Diagnosis and Treatment of Non-Muscle-Invasive Bladder Cancer.
AUTHORED: The Oregon Health & Science University, Pacific Northwest Evidence-Based Practice Center.
AND, obviously the
NCCN (National Comprehensive Cancer Network) and
AUA (American Urological Association) will take note of the results and it could easily influence or guide their decisions and content of future publications.
The anticipated completion date is
9th February 2015, and I think it is just an awesome opportunity that will have major benefits for Pacific Edge Diagnostics.
HyperLink: Emerging Approaches to Diagnosis & Treatment Bladder Cancer
As I understand it; The Centre for Reviews and Dissemination is a department of the University of York and PROSPERO is their International Prospective Register of Systematic Reviews; however the review will not be undertaken by the UK, it will be American.